Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the metabolic control status, cardiovascular risk and frequency of comorbidities in diabetic patients followed in tertiary treatment centers in Turkey.
Diabetes mellitus is one of the most common chronic diseases worldwide.The prevalence of diabetes is increased significantly in Türkiye, from 7.2 % in 2002 to 13.7% in 2012. This increasing prevalence leads to serious public health problems and a significant economic burden. Many important diseases such as hypertension and dyslipidemia accompany the picture in diabetic patients. The optimal treatment of diabetes and prevention of diabetic complications, especially the cardiovascular outcomes, is utmost important. Although achieving glycemic targets in patients with diabetes is of great importance, blood glucose is not the only predictor of cardiovascular outcome in diabetes. Optimization of other metabolic parameters such as lipids, arterial blood pressure (ABP), and body weight as well as a healthy lifestyle are utmost important.
Common problems in diabetic patients, such as sleep disorders and sexual dysfunction, affect glycemia regulation in these patients.There is little data on the frequency of these diseases in diabetic patients in Türkiye.
In the TEMD-1 study conducted in 2017, the rates of diabetic patients achieving metabolic goals and the factors affecting these rates were revealed in Turkish patients with diabetes. The findings obtained in the current study will be compared with the findings in 2017, and in addition, the frequency of comorbidities such as sleep disorder, sexual dysfunction, and depression will be tried to be revealed.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with diabetes mellitus | Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| There is no intervention. | Other | There is no intervention. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glycemia control status of Turkish adult patients with diabetes mellitus | Glycemia control will be defined as good control if the mean HbA1c level of patients < 7% or poor control if the mean HbA1c level of patient between 7% and 9% and very poor control if the mean HbA1c level of patient > 9% | 7 days |
| Blood pressure control status of Turkish adult patients with diabetes mellitus | Home blood pressure <135/85 mmHg or office blood pressure <140/90 mmHg will be defined as under control. | 7 days |
| Lipid control status of Turkish adult patients with diabetes mellitus. | Triglyceride < 150 mg/dl, LDL-C <55 mg/dl, <70 mg/dl and < 100 mg/dl according to the cardiovascular risk status, HDL-C > 40 mg/dl for men, and HDL-C > 50 mg/dl for women will be defined as under control. | 7 days |
| Weight control status of Turkish adult patients with diabetes mellitus. | Body mass index < 30 kg/m2 will be defined as under control. Weight and height will be combined to report body mass index in kg/m2. | 7 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with type 1 or type 2 diabetes who were under follow-up in the same tertiary endocrine unit for at least a year were enrolled.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alper Sonmez, Prof. | Ankara Guven Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gulhane School of Medicine Department of Endocrinology and Metabolism | Ankara | 06010 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42413349 | Derived | Sonmez A, Haymana C, Demirci I, Cetinarslan B, Gonen MS, Akbas EM, Yalin GY, Avci U, Tasci I, Salman S, Ersoy C, Bayram F, Satman I; TEMD-2 Study Group. Turkish cross-sectional survEy of glycemic and other Metabolic parameters in patients with type 2 Diabetes in 2023: Comparison with 2018 nationwide data (TEMD-2 study). J Diabetes Complications. 2026 May 27;40(9):109348. doi: 10.1016/j.jdiacomp.2026.109348. Online ahead of print. | |
| 42130190 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D012893 | Sleep Wake Disorders |
| D012735 | Sexual Dysfunction, Physiological |
| D003863 | Depression |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Derived |
| Sah Unal FT, Gokcay Canpolat A, Emral R, Haymana C, Demirci I, Salman S, Ersoy C, Bayram F, Satman I, Sonmez A, Corapcioglu D, Temd-Study Group. Polypharmacy and associated factors in patients with type 2 diabetes: a nationwide cross-sectional study (TEMD-2 polypharmacy study). Postgrad Med. 2026 May 13:1-10. doi: 10.1080/00325481.2026.2673267. Online ahead of print. |
| D009422 | Nervous System Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001523 | Mental Disorders |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |